| Performance Physical Therapy Of Idaho | |
|
450 W State St Ste 270, Eagle, ID 83616-6974 | |
| (925) 856-7007 | |
| Not Available |
| Full Name | Performance Physical Therapy Of Idaho |
|---|---|
| Type | Facility |
| Speciality | Physical Therapist |
| Location | 450 W State St Ste 270, Eagle, Idaho |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295234367 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | (* (Not Available)) | Primary |
| Provider Name | Matthew Candau |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1457746067 PECOS PAC ID: 9436470069 Enrollment ID: I20170425002757 |
News Archive
Celgene Corporation and Abraxis BioScience Inc. today jointly announced the signing of a definitive merger agreement in which Celgene has agreed to acquire Abraxis BioScience. Under the terms of the merger agreement, each share of Abraxis BioScience common stock will be converted into the right to receive an upfront payment of $58.00 in cash and 0.2617 shares of Celgene common stock.
The European Commission (EC) has approved expanded options for pre-treatment prior to use of QUTENZA (8% capsaicin patch). Before application the patient may now take an oral analgesic, or the treatment area may be pre-treated with a topical anaesthetic.1 The 8% capsaicin patch is the first and only licensed high concentration (8%) capsaicin cutaneous patch for the treatment of peripheral neuropathic pain in Europe.
Amedisys, Inc., one of America's leading home health nursing companies, today announced that Fortune magazine named Amedisys on its list of the 10 Best Stocks for 2010 in its issue dated December 21, 2009.
Searching through the mountains of published cancer research could be made easier for scientists, thanks to a new AI system.
ConjuChem Biotechnologies Inc. ("ConjuChem") (TSX:CJB) today announced the completion of the transaction providing $5 million in new, non-dilutive capital to the Company. The Superior Court of Québec has approved the previously announced plan of arrangement (the "Arrangement") under section 192 of the Canada Business Corporations Act (the "CBCA") involving ConjuChem and Colabor Income Fund ("Colabor"), among others, all as fully described in ConjuChem's management information circular dated July 17, 2009.
› Verified 2 days ago
| Provider Name | Chad S Neubauer |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1619398393 PECOS PAC ID: 5395168587 Enrollment ID: I20200707000769 |
News Archive
Celgene Corporation and Abraxis BioScience Inc. today jointly announced the signing of a definitive merger agreement in which Celgene has agreed to acquire Abraxis BioScience. Under the terms of the merger agreement, each share of Abraxis BioScience common stock will be converted into the right to receive an upfront payment of $58.00 in cash and 0.2617 shares of Celgene common stock.
The European Commission (EC) has approved expanded options for pre-treatment prior to use of QUTENZA (8% capsaicin patch). Before application the patient may now take an oral analgesic, or the treatment area may be pre-treated with a topical anaesthetic.1 The 8% capsaicin patch is the first and only licensed high concentration (8%) capsaicin cutaneous patch for the treatment of peripheral neuropathic pain in Europe.
Amedisys, Inc., one of America's leading home health nursing companies, today announced that Fortune magazine named Amedisys on its list of the 10 Best Stocks for 2010 in its issue dated December 21, 2009.
Searching through the mountains of published cancer research could be made easier for scientists, thanks to a new AI system.
ConjuChem Biotechnologies Inc. ("ConjuChem") (TSX:CJB) today announced the completion of the transaction providing $5 million in new, non-dilutive capital to the Company. The Superior Court of Québec has approved the previously announced plan of arrangement (the "Arrangement") under section 192 of the Canada Business Corporations Act (the "CBCA") involving ConjuChem and Colabor Income Fund ("Colabor"), among others, all as fully described in ConjuChem's management information circular dated July 17, 2009.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Performance Physical Therapy Of Idaho 1940 S Bonito Way Ste 190, Meridian, ID 83642-5618 Ph: (208) 287-9420 | Performance Physical Therapy Of Idaho 450 W State St Ste 270, Eagle, ID 83616-6974 Ph: (925) 856-7007 |
News Archive
Celgene Corporation and Abraxis BioScience Inc. today jointly announced the signing of a definitive merger agreement in which Celgene has agreed to acquire Abraxis BioScience. Under the terms of the merger agreement, each share of Abraxis BioScience common stock will be converted into the right to receive an upfront payment of $58.00 in cash and 0.2617 shares of Celgene common stock.
The European Commission (EC) has approved expanded options for pre-treatment prior to use of QUTENZA (8% capsaicin patch). Before application the patient may now take an oral analgesic, or the treatment area may be pre-treated with a topical anaesthetic.1 The 8% capsaicin patch is the first and only licensed high concentration (8%) capsaicin cutaneous patch for the treatment of peripheral neuropathic pain in Europe.
Amedisys, Inc., one of America's leading home health nursing companies, today announced that Fortune magazine named Amedisys on its list of the 10 Best Stocks for 2010 in its issue dated December 21, 2009.
Searching through the mountains of published cancer research could be made easier for scientists, thanks to a new AI system.
ConjuChem Biotechnologies Inc. ("ConjuChem") (TSX:CJB) today announced the completion of the transaction providing $5 million in new, non-dilutive capital to the Company. The Superior Court of Québec has approved the previously announced plan of arrangement (the "Arrangement") under section 192 of the Canada Business Corporations Act (the "CBCA") involving ConjuChem and Colabor Income Fund ("Colabor"), among others, all as fully described in ConjuChem's management information circular dated July 17, 2009.
› Verified 2 days ago
Allison Andrews Boldridge, P.T. Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 77 N Fisher Park Way, Eagle, ID 83616 Phone: 208-297-3039 | |
Serin Kim, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 77 N Fisher Park Way, Eagle, ID 83616 Phone: 208-297-3039 Fax: 208-416-6635 | |
Kathryn L Stednitz, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 21 N Fisher Park Way, Eagle, ID 83616 Phone: 208-514-0670 | |
Christopher Fox, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 645 E State St Ste 101, Eagle, ID 83616 Phone: 208-939-9594 Fax: 208-939-9828 | |
Emily Verheijen, DPT Physical Therapist Medicare: Medicare Enrolled Practice Location: 507 S Fitness Pl Ste 110, Eagle, ID 83616 Phone: 208-629-1030 Fax: 208-346-7618 | |
Ms. Megan Meduna, MSPT Physical Therapist Medicare: Medicare Enrolled Practice Location: 457 S Fitness Pl Ste 100, Eagle, ID 83616 Phone: 208-939-3332 Fax: 208-939-3338 | |
Elise Talboy, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 516 S Wooddale Pl, Eagle, ID 83616 Phone: 208-477-7363 |